|
|
| |
|
As ibogaine is not regulated in Canada as it is in the US, this affords
us a unique opportunity to conduct much needed research on ibogaine-assisted
therapy. |
|
| |
| |
Ibogaine Outcome Study:
A Progress Report on the Iboga Therapy House
Sandra Karpetas
Project Director
Iboga Therapy House
I am pleased to announce that through the generous funding, assistance
and mentorship of MAPS and after many long months of setbacks and
challenges, the Iboga Therapy House is now a non-profit entity ready
to open the doors of our ibogaine clinic in Canada.
Our program is based on a holistic harm reduction and health promotion-based
approach to recovery and personal exploration. It is our goal to facilitate
an improvement in the quality of life of those seeking recovery from
chemical dependence to substances such as heroin, methadone and
other opiates, crack, cocaine, methamphetamine and alcohol in a safe
and supportive environment to support the psychospiritual and therapeutic
exploration of deeper issues through processes facilitated by the
powerful experience that ibogaine may catalyze.
This project aims to complement the range of existing drug treatment
options with an Ibogaine therapy service that recognizes that reductions
in problematic use, changes in patterns of use toward forms of use
that are less problematic, and sustained periods of prolonged abstinence
all contribute to healthier lifestyles, increase resiliency and in
turn contribute to improvements in quality of life for the drug addicted
population.
Our staff consists of two Emergency Medical Technicians (1st Aid
Level 3) to be present in case of an emergency, nine facilitators
with a wide range of skills to monitor and support the participants
in their treatment, two of which are professional substance abuse
counselors, plus a host of community volunteers offering aftercare
services such as bodywork/massage therapy, ecstatic dance, guided
breathwork, reiki, light exercise such as yoga and nutritional planning.
Several doctors have also requested to observe the treatments.
As ibogaine is not regulated in Canada as it is in the US, this affords
us a unique opportunity to conduct much needed research on ibogaine-assisted
therapy.
MAPS will provide the evaluation and research component by conducting
a one-year follow-up study using information collected from 20 people
treated at the Iboga Therapy House. Valerie Mojeiko of MAPS and Leah
Martin of the Iboga Therapy House will coordinate the study.
The evaluation tools have been chosen to be reliable, well validated,
and repeatable. Special consideration is given to measures that assess
several indicators of success in addition to abstinence. The primary
measure is the Addiction Severity Index, a widely used index that
measures seven problem areas to obtain a comprehensive picture of
a person’s life and lifestyle. Secondary measures include the
Beck Depression and Anxiety Inventories, Subjective and Objective
Opiate Withdrawal Scales, Peak Experience Profile (for measuring content
of Ibogaine experience and how it relates to recovery), and pain and
craving scales. We hope to show that ibogaine-assisted therapy is
associated with extended periods of abstinence, and that intensity
of the ibogaine experience will be associated with longer periods
of abstinence.
A copy of the protocol design can be found on the MAPS website
on the Ibogaine research page at www.maps.org/ibogaine
Over the last few months we have developed a program manual that
is intended to serve as a protocol for our own upcoming program
and as a potential model for ibogaine treatment and research in Canada.
It is of great interest to develop strategies for communicating
with people in other fields of interest or study, to open dialogue
about other psychedelics and entheogenic substances that have value
as therapeutic agents of self-discovery. Increased interest and understanding of these potentials could lead to changes in the societal
perception of psychedelics and lead to educated changes in drug policy,
opening the door towards further research into a range of potential
beneficial uses in legal contexts.
We are now accepting applications for Ibogaine-assisted therapy from
chemically dependant applicants wishing to participate in our study.
We plan to conduct our first treatments in November 2005 and to complete
the treatment phase of this study in the spring of 2006. For more
information about our program, how to apply and the costs of treatment
please see our website at: www.ibogatherapyhouse.net
Many thanks to all the supporters of MAPS for your assistance in
making this project a reality!
If you would like to make a donation to this project go to: www.maps.org/donate and specify “Iboga Therapy House"
|